Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains Momentum
Aurentis Capital Group Announces Technology-Driven Trading Platform for Global Markets
TMX Group Limited Completes Acquisition of RAFI Indices from Research Affiliates
Focus Graphite Chairman Converts Final C$835,000 Loan to Equity at a Premium to Market
Hong Kong emerges as top professional services platform for Mainland enterprises going global
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the…
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the…
LYON, France and CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
LYON, France and CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
Todd Edwards Chief Commercial Officer, Arcutis Biotherapeutics Industry veteran with deep commercial experience in dermatology…
Todd Edwards Chief Commercial Officer, Arcutis Biotherapeutics Industry veteran with deep commercial experience in dermatology…
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD…
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD…
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting…
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting…
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and…
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and…
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward…
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward…
– Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated…
– Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated…
BEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage…
BEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage…